Market Research Logo

PharmaPoint: Glaucoma - Global Drug Forecast and Market Analysis to 2026

PharmaPoint: Glaucoma - Global Drug Forecast and Market Analysis to 2026

Summary

Glaucoma is the leading cause of irreversible vision loss, worldwide. The term glaucoma includes many different diseases, which are associated with differing risk factors, symptoms, treatment, and prognosis. All forms of glaucoma are characterized by the loss of the retinal ganglion cells and their axons that make up the optic nerve, which results in a cupping of the optic nerve head. This leads to optic nerve damage and visual field loss. Raised intraocular pressure (IOP) is the primary risk factor for glaucoma, and progression of disease will normally stop if the IOP is lowered by 30-50%. Consequently, treatment options for glaucoma are developed around lowering the IOP. Although it is possible to slow the progression of glaucoma using current treatment options, it is not possible to reverse vision loss that has resulted from the disease.

Most drugs prescribed for glaucoma can be placed into one of four drug classes. Prostaglandin analogues (PGAs) are generally used as a first-line treatment, with beta blockers (BBs), alpha adrenergic receptor agonists (AAs), and carbonic anhydrase inhibitors (CAIs) also frequently used, albeit generally as second-line therapies in combination with PGAs. Certain combinations of available drugs are marketed as part of fixed-dose combination (FDC) therapies. Cholinergic agonists, also known as miotics, can also be used for the treatment of glaucoma, although they are much less commonly prescribed compared with PGAs, BBs, AAs, and CAIs.

Scope

  • Overview of glaucoma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline Glaucoma market revenue from 2016-2026. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting glaucoma therapeutics sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global CDI therapeutics and prophylactics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global glaucoma therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the glaucoma therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.


1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
2.1 Solid Growth Is Projected for the Glaucoma Market between 2016 and 2026
2.2 The Development of Drugs with Novel MOAs Marks a Shift in Glaucoma Corporate Strategy
2.3 Some Unmet Need Remains for Glaucoma, In Particular Improving Patient Compliance
2.4 Opportunities Remain for Products that Further Address Unmet Needs in the Glaucoma Market
2.5 Late-Stage Pipeline Drugs Entering the Glaucoma Market Are Poised to Drive Growth
2.6 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Introduction
4.2 Etiology and Pathophysiology
4.2.1 Etiology
4.2.2 Pathophysiology
4.3 Classification
4.4 Symptoms
4.5 Prognosis and Quality of Life
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.4.3 Total Prevalent Cases of POAG
5.4.4 Total Prevalent Cases of PACG
5.4.5 Total Prevalent Cases of NTG and PPG
5.4.6 Total Prevalent Cases of SG
5.4.7 Diagnosed Prevalent Cases
5.4.8 Diagnosed Incident Cases of Acute PACG
5.5 Epidemiological Forecast for Glaucoma (2016-2026)
5.5.1 Total Prevalent Cases of POAG
5.5.2 Age-Specific Total Prevalent Cases of POAG
5.5.3 Sex-Specific Total Prevalent Cases of POAG
5.5.4 Diagnosed Prevalent Cases of POAG
5.5.5 Total Prevalent Cases of PACG
5.5.6 Age-Specific Total Prevalent Cases of PACG
5.5.7 Sex-Specific Total Prevalent Cases of PACG
5.5.8 Diagnosed Prevalent Cases of PACG
5.5.9 Total Prevalent Cases of NTG
5.5.10 Diagnosed Prevalent Cases of NTG
5.5.11 Total Prevalent Cases of PPG
5.5.12 Diagnosed Prevalent Cases of PPG
5.5.13 Total Prevalent Cases of SG
5.5.14 Diagnosed Prevalent Cases of SG
5.5.15 Diagnosed Incident Cases of Acute PACG
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis
6 Disease Management
6.1 Diagnosis Overview
6.2 Treatment Overview
6.2.1 Treatment Guidelines
6.2.2 Leading Prescribed Drugs
6.2.3 Clinical Practice
6.3 US
6.4 5EU
6.5 Japan
7 Competitive Assessment
7.1 Overview
7.2 Product Profiles - Major Brands, Prostaglandin Analogues
7.2.1 Xalatan (latanoprost)
7.2.2 Lumigan (bimatoprost)
7.2.3 Travatan (travoprost)
7.2.4 Tapros (tafluprost)
7.2.5 Vyzulta (latanoprostene bunod)
7.3 Product Profiles, Fixed-Dose Combination Therapies
7.3.1 Overview
7.3.2 Efficacy
7.3.3 Safety
7.3.4 Forecast
7.4 Product Profiles, Beta Blockers (numerous brands)
7.4.1 Overview
7.4.2 Efficacy
7.4.3 Safety
7.4.4 Forecast
7.5 Product Profiles, Alpha-Adrenergic Agonists (numerous brands)
7.5.1 Overview
7.5.2 Efficacy
7.5.3 Safety
7.5.4 Forecast
7.6 Product Profiles, Carbonic Anhydrase Inhibitors (numerous brands)
7.6.1 Overview
7.6.2 Efficacy
7.6.3 Safety
7.6.4 Forecast
7.7 Product Profiles, Cholinergic Agonists (Miotics) (numerous brands)
7.7.1 Overview
7.7.2 Efficacy
7.7.3 Safety
7.7.4 Forecast
7.8 Product Profiles - Major Brands, Rho Kinase Inhibitors
7.8.1 Glanatec (ripasudil)
8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Improved Patient Compliance
8.2.1 Unmet Need
8.2.2 Gap Analysis
8.2.3 Opportunity
8.3 Treatment Options with Greater IOP-Lowering Ability
8.3.1 Unmet Need
8.3.2 Gap Analysis
8.3.3 Opportunity
8.4 Neuroprotective Drugs
8.4.1 Unmet Need
8.4.2 Gap Analysis
8.4.3 Opportunity
8.5 Improved Diagnosis and Monitoring
8.5.1 Unmet Need
8.5.2 Gap Analysis
8.5.3 Opportunity
9 Pipeline Assessment
9.1 Overview
9.2 Clinical Trial Mapping
9.2.1 Clinical Trials by Class, Development Phase and Region
9.3 Promising Drugs in Clinical Development
9.3.1 Rhopressa (netarsudil mesylate)
9.3.2 Roclatan (netarsudil mesylate + latanoprost)
9.3.3 Bimatoprost SR
9.3.4 OTX-TP
9.3.5 DE-117
9.3.6 SJP-0135
9.4 Promising Drugs in Early-Stage Development
9.4.1 ENV-515
9.4.2 Latanoprost SR Products
9.5 Other Drugs in Development
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Profiles
10.3.1 Allergan
10.3.2 Alcon (Novartis)
10.3.3 Santen
10.3.4 Pfizer
10.3.5 Otsuka
10.3.6 Valeant
10.3.7 Aerie Pharmaceuticals
10.3.8 Ocular Therapeutix
11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global Issues
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers
12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.3.1 Forecasting Methodology
12.3.2 Diagnosed Patients
12.3.3 Percent Drug-Treated Patients
12.3.4 Drugs Included in Each Therapeutic Class
12.3.5 Launch and Patent Expiry Dates
12.3.6 General Pricing Assumptions
12.3.7 Individual Drug Assumptions
12.3.8 Generic Erosion
12.3.9 Pricing of Pipeline Agents
12.4 Primary Research - KOLs Interviewed for This Report
12.5 Primary Research - Payers Interviewed for This Report
12.6 Primary Research - Prescriber Survey
12.7 About the Authors
12.7.1 Analysts
12.7.2 Therapy Area Director
12.7.3 Epidemiologist
12.7.4 Managing Epidemiologists
12.7.5 Global Director of Therapy Analysis and Epidemiology
12.7.6 Global Head of Healthcare
12.8 About GlobalData
12.9 Contact Us
12.10 Disclaimer
1.1 List of Tables
Table 1: Glaucoma: Key Metrics in the 7MM
Table 2: Symptoms of Glaucoma
Table 3: Risk Factors and Comorbidities for Glaucoma
Table 4: 7MM, Total Prevalent Cases of POAG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026
Table 5: 7MM, Diagnosed Prevalent Cases of POAG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026
Table 6: 7MM, Total Prevalent Cases of PACG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026
Table 7: 7MM, Diagnosed Prevalent Cases of PACG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026
Table 8: 7MM, Total Prevalent Cases of NTG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026
Table 9: 7MM, Diagnosed Prevalent Cases of NTG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026
Table 10: 7MM, Total Prevalent Cases of PPG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026
Table 11: 7MM, Diagnosed Prevalent Cases of PPG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026
Table 12: 7MM, Total Prevalent Cases of SG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026
Table 13: 7MM, Diagnosed Prevalent Cases of SG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026
Table 14: 7MM, Diagnosed Incident Cases of Acute PACG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026
Table 15: Diagnostic Tests for Glaucoma
Table 16: Drug Classes Used to Treat Glaucoma
Table 17: Treatment Guidelines for Glaucoma
Table 18: Most-Prescribed Drugs for Glaucoma by Class in the 7MM, 2016
Table 19: Country Profile - US
Table 20: Country Profile - 5EU
Table 21: Country Profile - Japan
Table 22: Product Profile - Xalatan
Table 23: Observed Clinical Efficacy of Xalatan in a Phase IV Trial
Table 24: Number of Treatment-Related AEs in a Phase IV Trial for Xalatan
Table 25: Xalatan SWOT Analysis, 2017
Table 26: Product Profile - Lumigan
Table 27: Results from a Phase IV Clinical Trial Comparing the Change in IOP After One Year In Patients Taking Lumigan, Xalatan, or Travatan
Table 28: Comparison of Results from Two Phase IV Clinical Trials Assessing the Change in IOP In Patients Who Receive One of Two Doses Of Lumigan
Table 29: Comparison of Reported AEs from Patients Receiving Lumigan 0.01% and Lumigan 0.03%
Table 30: Lumigan SWOT Analysis, 2017
Table 31: Product Profile - Travatan
Table 32: Travatan SWOT Analysis, 2017
Table 33: Product Profile - Tapros
Table 34: Reduction in IOP Observed in a Phase IV Trial Comparing Tapros and Xalatan
Table 35: Tapros AEs
Table 36: Tapros SWOT Analysis, 2017
Table 37: Product Profile - Vyzulta
Table 38: Observed Clinical Efficacy of Vyzulta in Two Phase III Trials
Table 39: Safety Profile of Vyzulta Observed in the LUNAR Phase III Trial
Table 40: Vyzulta SWOT Analysis, 2017
Table 41: FDCs Available in the 7MM
Table 42: Beta Blockers Available in the 7MM
Table 43: AA Monotherapies Available in the 7MM
Table 44: CAIs Available in the 7MM
Table 45: Results from a Phase III Clinical Trial Comparing the Change in IOP in Glaucoma Patients After Administration of Azopt, Trusopt, or Timolol
Table 46: Frequently Reported AEs During a Phase III Clinical Trial Comparing Azopt, Trusopt, and Timolol
Table 47: Cholinergic Agonists Available in the 7MM
Table 48: Product Profile - Glanatec
Table 49: Results from Two Phase III Clinical Trials Comparing the Change in IOP When Glanatec Is Used Adjunctively with Timolol or Xalatan
Table 50: Frequently Reported AEs During Two Phase III Clinical Trials Assessing the Safety and Efficacy of Glanatec When Used Adjunctively with Timolol or Xalatan
Table 51: Glanatec SWOT Analysis, 2017
Table 52: Promising Products in Late-Stage Clinical Development for Treatment of Glaucoma
Table 53: Product Profile - Rhopressa
Table 54: Most Frequently Observed AEs for Rhopressa and Timolol in Rocket-4 Phase III Trial
Table 55: Rhopressa SWOT Analysis, 2017
Table 56: Product Profile - Roclatan
Table 57: Mean Diurnal IOP Change over 90 days of Treatment with Roclatan Compared With Latanoprost and Rhopressa
Table 58: Common AEs Observed in the Mercury-1 and Mercury-2 Phase III Trials
Table 59: Roclatan SWOT Analysis, 2017
Table 60: Product Profile - Bimatoprost SR
Table 61: Data Presented from a Phase II Trial Comparing the Efficacy of Bimatoprost SR with Topical Bimatoprost 0.3%
Table 62: Bimatoprost SR SWOT Analysis, 2017
Table 63: Product Profile - OTX-TP
Table 64: Reduction in Diurnal IOP from Baseline Following Treatment with OTX-TP and Timolol
Table 65: OTX-TP SWOT Analysis, 2017
Table 66: Product Profile - DE-117
Table 67: AEs Reported in the Different Arms of Phase II Clinical Trials of DE-117
Table 68: DE-117 SWOT Analysis, 2017
Table 69: Product Profile - SJP-0135
Table 70: SJP-0135 SWOT Analysis, 2017
Table 71: Developmental Phase II Latanoprost SR Products for the Treatment of Glaucoma
Table 72: Drugs in Development for Glaucoma, 2017
Table 73: Key Companies in the Glaucoma Market in the 7MM, 2017
Table 74: Allergan’s Glaucoma Portfolio Assessment, 2017
Table 75: Alcon’s Glaucoma Portfolio Assessment, 2017
Table 76: Santen’s Glaucoma Portfolio Assessment, 2017
Table 77: Pfizer’s Glaucoma Portfolio Assessment, 2017
Table 78: Otsuka’s Glaucoma Portfolio Assessment, 2017
Table 79: Valeant’s Glaucoma Portfolio Assessment, 2017
Table 80: Aerie Pharmaceuticals’ Glaucoma Portfolio Assessment, 2017
Table 81: Ocular Therapeutics’ Glaucoma Portfolio Assessment, 2017
Table 82: Global Sales Forecast ($M) for Glaucoma by Product, 2016-2026
Table 83: Glaucoma Market - Global Drivers and Barriers, 2016-2026
Table 84: Key Events Impacting Sales for Glaucoma in the US, 2016-2026
Table 85: Glaucoma Market - Drivers and Barriers in the US, 2016-2026
Table 86: Key Events Impacting Sales for Glaucoma in the 5EU, 2016-2026
Table 87: Glaucoma Market - Drivers and Barriers in the 5EU, 2016-2026
Table 88: Key Events Impacting Sales for Glaucoma in Japan, 2016-2026
Table 89: Glaucoma Market - Drivers and Barriers in Japan, 2016-2026
Table 90: Sources Used For Diagnosed Glaucoma Incidence and Segmentation in the 7MM
Table 91: Projected Launch Dates for Glaucoma
Table 92: Key Historical and Projected Patent Expiry Dates for Glaucoma
Table 93: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
1.2 List of Figures
Figure 1: Global Sales Forecast by Country for Glaucoma in 2016 and 2026
Figure 2: Analysis of the Company Portfolio Gap in Glaucoma During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of Glaucoma During the Forecast Period
Figure 4: The Flow of AqH in an Eye with OAG and ACG
Figure 5: The Different Causes of Secondary Glaucoma
Figure 6: The Aqueous Humor Cycle
Figure 7: Nerve Damage - Cupping
Figure 8: Different Classifications of Glaucoma
Figure 9: 7MM, Age-Standardized Total Prevalence of POAG, Men and Women, Ages ≥40 Years, 2016
Figure 10: 7MM, Age-Standardized Total Prevalence of PACG, Men and Women, Ages ≥40 Years, 2016
Figure 11: 7MM, Sources Used to Forecast Total Prevalent Cases of POAG
Figure 12: 7MM, Sources Used to Forecast Total Prevalent Cases of PACG
Figure 13: 7MM, Sources Used to Forecast Total Prevalent Cases of NTG
Figure 14: 7MM, Sources Used to Forecast Total Prevalent Cases of PPG
Figure 15: 7MM, Sources Used to Forecast Total Prevalent Cases of SG
Figure 16: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Acute PACG
Figure 17: 7MM, Age-Specific Total Prevalent Cases of POAG, Both Sexes, Ages ≥40 Years, N, 2016
Figure 18: 7MM, Sex-Specific Total Prevalent Cases of POAG, Both Sexes, Ages ≥40 Years, N, 2016
Figure 19: 7MM, Age-Specific Total Prevalent Cases of PACG, Both Sexes, Ages ≥40 Years, N, 2016
Figure 20: 7MM, Sex-Specific Total Prevalent Cases of PACG, Both Sexes, Ages ≥40 Years, N, 2016
Figure 21: Glaucoma Clinical Treatment Flowchart
Figure 22: Drug Launch and Patent Expiration Timelines of PGAs for Glaucoma in the 7MM
Figure 23: Drug Launch and Patent Expiration Timelines of FDCs for Glaucoma in the 7MM
Figure 24: Unmet Need and Opportunity in Glaucoma, 2017
Figure 25: Bullseye Diagram of Products in Clinical Development for Glaucoma, 2017
Figure 26: Number of Ongoing Phase I-III Clinical Trials in Various Drug Classes for Glaucoma in the 7MM as of September 2017
Figure 27: Regional Shares of Ongoing Glaucoma Clinical Trials in the 7MM
Figure 28: Key Phase III Trials for the Promising Pipeline Agents that GlobalData Expects be Licensed for Glaucoma in the 7MM During the Forecast Period
Figure 29: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of Glaucoma During the Forecast Period
Figure 30: Clinical and Commercial Positioning of Rhopressa
Figure 31: Clinical and Commercial Positioning of Roclatan
Figure 32: Clinical and Commercial Positioning of Bimatoprost SR
Figure 33: Clinical and Commercial Positioning of OTX-TP
Figure 34: Clinical and Commercial Positioning of DE-117
Figure 35: Clinical and Commercial Positioning of SJP-0135
Figure 36: Global Sales of Branded Products for Glaucoma by Company in 2016 and 2026
Figure 37: Analysis of the Company Portfolio Gap in Glaucoma During the Forecast Period
Figure 38: Global (7MM) Sales Forecast by Country for Glaucoma in 2016 and 2026
Figure 39: Sales Forecast by Class for Glaucoma in the US in 2016 and 2026
Figure 40: Sales Forecast by Class for Glaucoma in the 5EU in 2016 and 2026
Figure 41: Sales Forecast by Class for Glaucoma in Japan in 2016 and 2026

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report